Our Pricing

Wegovy vs Orlistat UK Pharmacy Comparison: Which Weight Loss Treatment Works Best?

Published on: June 03, 2026

Choosing between wegovy vs orlistat uk pharmacy options requires understanding how these two MHRA-licensed weight loss treatments differ in mechanism, efficacy, and suitability. As a UK-registered pharmacy with thousands of weight management consultations completed, we've guided patients through this exact decision daily, and this comprehensive comparison draws on clinical trial data and real-world experience to help you make an informed choice.

How Wegovy and Orlistat Work: Fundamentally Different Mechanisms

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone to regulate appetite, slow gastric emptying, and enhance feelings of fullness [1]. Administered as a once-weekly subcutaneous injection, it works centrally on brain appetite centres and peripherally on the digestive system to reduce calorie intake naturally.

Orlistat operates through an entirely different mechanism—it inhibits pancreatic and gastric lipases, enzymes responsible for breaking down dietary fats [2]. By blocking approximately 30% of dietary fat absorption, orlistat reduces calorie intake mechanically rather than hormonally. It's taken as a 120mg capsule three times daily with meals containing fat.

This fundamental difference means Wegovy addresses appetite and satiety signals, whilst orlistat focuses purely on nutrient absorption. Neither medication is a substitute for lifestyle modification—both require commitment to dietary changes and increased physical activity for optimal results, as confirmed by NICE guidance on weight management interventions.

Clinical Efficacy: Wegovy vs Orlistat Weight Loss Results

The STEP 1 trial demonstrated that adults using Wegovy achieved an average 14.9% total body weight reduction over 68 weeks, with 86.4% of participants losing at least 5% of their baseline weight [1]. In contrast, orlistat trials typically show average weight loss of 2.9kg more than placebo over 12 months, equating to approximately 3-5% additional body weight reduction [2].

Head-to-head comparisons aren't available, but when examining clinical trial data side by side, semaglutide-based treatments consistently produce two to three times greater weight reduction than orlistat. The STEP programme also recorded significant improvements in cardiometabolic markers including HbA1c, blood pressure, and lipid profiles [3].

However, efficacy must be balanced against individual circumstances. Orlistat may be more appropriate for patients who prefer oral medication, have contraindications to GLP-1 agonists, or require a lower-cost option. Our clinical team assesses medical history, BMI, comorbidities, and personal preferences during consultation to recommend the most suitable treatment.

Realistic Expectations for Weight Loss Outcomes

Clinical trials represent controlled conditions—real-world results vary based on adherence, dietary modifications, exercise habits, and metabolic factors. We've observed that patients who combine either medication with structured nutrition plans and regular physical activity achieve results closer to trial averages, whilst those relying solely on medication without lifestyle changes see diminished outcomes. Your UK prescriber will discuss realistic weight loss targets during your free consultation, typically aiming for 5-10% body weight reduction as an initial goal that delivers meaningful health benefits.

Side Effect Profiles: What to Expect from Each Treatment

Wegovy's most common adverse effects are gastrointestinal: nausea (44% of trial participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These symptoms typically emerge during dose escalation and diminish over 4-8 weeks as the body adjusts. Rare but serious risks include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies, not confirmed in humans).

Orlistat's side effects relate directly to its fat-blocking mechanism—oily stools, faecal urgency, flatulence with discharge, and increased bowel movements affect up to 27% of users [2]. These effects worsen with high-fat meals and can be socially disruptive. However, orlistat carries no systemic absorption, meaning it doesn't interact with most medications or cause metabolic disturbances.

From a practical standpoint, Wegovy's side effects are typically manageable through dose titration and dietary adjustments (smaller meals, avoiding high-fat foods initially), whilst orlistat's effects require strict dietary fat restriction—generally below 30% of total calories. Patients who struggle with gastrointestinal symptoms on one medication may tolerate the other better, and our pharmacists provide detailed management strategies during dispensing.

Eligibility Criteria and Prescribing Guidelines in the UK

NICE guidelines recommend considering pharmacological weight management for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia [4]. Wegovy is specifically licensed for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity, who have demonstrated inability to achieve weight loss through diet and exercise alone.

Orlistat has broader eligibility—it can be prescribed for BMI ≥28 kg/m² with risk factors, or BMI ≥30 without comorbidities. It's also available over the counter as a 60mg formulation (Alli), though the prescription-strength 120mg version (Xenical) delivers superior efficacy. Orlistat may be preferred for patients with contraindications to GLP-1 agonists, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Both medications require ongoing monitoring. NICE recommends discontinuing treatment if patients fail to lose at least 5% of initial body weight after 12 weeks at therapeutic dose. During your online consultation, our UK prescribers assess your medical history, current medications, weight loss goals, and previous treatment attempts to determine which option aligns with clinical guidelines and your individual needs.

Contraindications and Special Populations

Wegovy is contraindicated in pregnancy, with medullary thyroid carcinoma history, and in patients with severe gastrointestinal disease. Orlistat should be avoided in chronic malabsorption syndrome, cholestasis, and during pregnancy. Both require caution in patients taking anticoagulants (orlistat can affect vitamin K absorption), antidiabetic medications (dose adjustments may be needed), or with history of pancreatitis. Our clinical assessment identifies these factors before prescribing, ensuring patient safety remains paramount.

Dosing, Administration, and Treatment Duration

Wegovy follows a structured dose-escalation schedule over 16-20 weeks, starting at 0.25mg weekly and increasing monthly to the maintenance dose of 2.4mg weekly [1]. This gradual titration minimises gastrointestinal side effects whilst allowing physiological adaptation. The pre-filled injection pens are administered subcutaneously in the abdomen, thigh, or upper arm—most patients find the process straightforward after initial guidance.

Orlistat is taken as one 120mg capsule with each main meal containing fat, up to three times daily. If a meal is missed or contains no fat, the dose should be omitted. Patients must take a daily multivitamin supplement (at bedtime, separate from orlistat) because the medication reduces absorption of fat-soluble vitamins A, D, E, and K [2].

Treatment duration varies by individual response. Clinical trials evaluated Wegovy for up to 68 weeks, with many patients continuing beyond that timeframe under medical supervision. Orlistat is typically prescribed for 12-week initial courses, with continuation dependent on achieving ≥5% weight loss. Both treatments are most effective as part of long-term weight management programmes rather than short-term interventions—our pharmacists provide ongoing support and monitoring throughout your treatment journey.

Practical Considerations for Daily Life

Wegovy's once-weekly dosing offers convenience compared to orlistat's thrice-daily regimen, particularly for patients with busy schedules or those who struggle with medication adherence. However, the injection format may deter needle-averse individuals, whilst orlistat's oral capsules are more familiar. Storage requirements differ too—Wegovy pens must be refrigerated until first use (then can be stored at room temperature for 28 days), whereas orlistat capsules require standard room-temperature storage. Consider your lifestyle, travel habits, and personal preferences when discussing options with your prescriber.

Cost Comparison and Value for UK Patients

At Cured Pharmacy, Wegovy is available from £79.00 per pen, with transparent pricing displayed before your free consultation begins. This represents competitive UK pricing with no hidden fees—what you see is what you pay, including prescriber assessment and discreet home delivery.

When evaluating cost-effectiveness, consider the total treatment expense over time, including consultation fees, medication costs, and potential for dose adjustments. Wegovy's once-weekly dosing means one pen lasts one week, whilst orlistat requires 21 capsules weekly (three daily for seven days). Both medications represent an investment in health that should be weighed against potential medical costs of obesity-related complications—cardiovascular disease, type 2 diabetes, and joint problems.

Our pharmacy guarantees the lowest prices in the UK for genuine, MHRA-licensed medications. We've eliminated the markup typically added by high-street chains, passing savings directly to patients. Your total cost depends on treatment duration and prescriber-recommended dose, which our clinical team determines based on your individual response and weight loss progress. Many patients find that achieving clinically significant weight loss delivers value far beyond the monetary investment through improved health markers, reduced comorbidity risk, and enhanced quality of life.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
3. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (Clinical guideline CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications including diet and exercise. Neither Wegovy nor orlistat is suitable for everyone—your prescriber will assess your medical history to determine the most appropriate treatment option.